LONDON (Reuters) - GlaxoSmithKline (GSK.L) has withdrawn from the race to buy Pfizer’s (PFE.N) consumer healthcare business, the British company said on Friday, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion.
It was not immediately clear whether there were other offers for the business, which includes Advil painkillers and Centrum vitamins, following this week’s deadline for binding bids.
GSK was seen as the frontrunner to buy the assets, after Reckitt Benckiser (RB.L) quit the race late on Wednesday.
“While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation,” GSK Chief Executive Emma Walmsley said in a statement.
GSK shares rose 3 percent, as investors’ concerns about a potential dividend cut eased.
Sources familiar with the matter said on Thursday there might still be interest in the Pfizer business, or the U.S. firm could decide against a sale.
Pfizer said on Friday it continued to evaluate potential alternatives for the business, which include a spin-off, sale or other transaction, as well as retaining it.
“We have not yet made a decision, but continue to expect to make one in 2018,” a spokesman said.
Pfizer is the world’s fifth-largest player in consumer health with 2.5 percent of a market bolstered by aging populations and growing interest in health and wellness.
The business, which also includes Chapstick lip balm and Caltrate supplements, came to market at a bad time for both GSK and Reckitt.
Pfizer’s hope of proceeds of around $20 billion, or about 20 times the unit’s core earnings according to Bernstein analysts, contrasted with both companies’ need for financial discipline.
Buying the Pfizer business would have been the boldest move to date for Walmsley, who took over at GSK last April. But the wisdom of a deal split opinion among investors, with some worried about the risk to the company’s dividend.
Acquiring additional consumer health assets at a reasonable price could have been a fairly safe way to boost earnings, since scale is key in over-the-counter remedies, but it could have distracted from fixing GSK’s core pharma division.
That is a particular headache for Walmsley - a consumer products veteran who worked for 17 years at L’Oreal (OREP.PA) - since she has her work cut out to persuade the market she is the right person to lead Britain’s top pharmaceuticals company.
Last month, in a bid to reassure investors, she spelt out more clearly than before that her first priority was improving performance in prescription drugs, followed by dividend payments and only after that acquisitions.
The overhaul of the drugs business, which has produced fewer blockbuster medicines than rivals in